Two plaintiffs with Parkinson's disease have lost their attempt to compel a drug company to continue giving them an experimental treatment. A federal judge in New York refused to grant a preliminary injunction sought by the patients, who claimed Amgen overreacted to data showing the treatment risked worsening their conditions. The judge found that the patients, who he called "courageous individuals," knew from the consent form that their participation in the study was "not a matter of right."
June 09, 2005 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Two plaintiffs afflicted with Parkinson’s disease have lost their attempt to compel a drug company to continue giving them an experimental treatment.
Southern District Judge P. Kevin Castel upheld the right of New York-based Amgen Inc. to terminate experimental trials for treatment of the neurodegenerative disease by refusing to grant a preliminary injunction sought by two patients who claimed the company overreacted to data showing the treatment risked worsening their conditions.
This conference aims to help insurers and litigators better manage complex claims and litigation.
Recognizing innovation in the legal technology sector for working on precedent-setting, game-changing projects and initiatives.
Legalweek New York explores Business and Regulatory Trends, Technology and Talent drivers impacting law firms.
THE CITY OF FORT LAUDERDALE, FL INVITES YOUR INTEREST FOR THE POSITION OF CITY ATTORNEYWelcome to the City of Fort Lauderdale. Click on the ...
McCarter & English, LLP seeks an associate for an in-person position in McCarter s Washington DC office. McCarter s energy transactiona...
TIRED OF LAW? MOTIVATED REAL ESTATE AGENTS FOR F/T POSITION WITH TOP RESIDENTIAL REAL ESTATE TEAM AT BROWN HARRIS STEVENS RESIDENTIAL SALE...
